Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China. 30895535 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Our results, together with the available literature, provide reassurance that breast-conserving therapy is a safe local treatment option to offer to BRCA1 mutation carriers with invasive breast cancer. 29727326 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE We performed this study to define germline mutations in BRCA1/2 and their implication in breast cancer among young women from eastern Algeria diagnosed or treated with primary invasive breast cancer at the age of 40 or less who were referred to Anti-Cancer Center of Setif, Algeria. 26997744 2016
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE We evaluated 200 Bulgarian women with primary invasive breast cancer and with personal/ family history of breast cancer for the presence of unequivocally damaging germline mutations in BRCA1/2 using Sanger sequencing. 26183948 2015
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). 25187270 2014
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE All women with invasive breast cancer and a BRCA1 mutation should be considered to be candidates for chemotherapy. 23381743 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 AlteredExpression disease BEFREE We therefore studied HIF-1α overexpression in ductal carcinoma in situ (DCIS), an established precursor of invasive breast cancer.We used immunohistochemistry to examine the expression of the hypoxia markers HIF-1α, CAIX and Glut-1 in DCIS and available invasive carcinoma lesions of 32 BRCA1, 16 BRCA2 and 77 non-BRCA mutation-related cases. 23409121 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Interestingly, nuclear Kaiso was also abundant in BRCA1-associated breast cancer (p<0.001) and invasive breast cancer overexpressing EGFR (p = 0.019). 22662240 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Of the 196 patients with invasive breast carcinoma, there were 44 (22%) with a deleterious BRCA1 mutation and 27 (14%) with a deleterious BRCA2 mutation. 22591913 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE In one asymptomatic BRCA2 carrier (0.7%) an occult small invasive breast cancer was diagnosed, while in 6 asymptomatic carriers (4.0% BRCA1 and 4.3% BRCA2) and in 5 symptomatic carriers (2.5% BRCA1 and 10.7% BRCA2) DCIS was detected at prophylactic mastectomy. 20134318 2010
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE BRCA1 carriers aged > or = 50 at diagnosis of first invasive breast cancer were more likely to have an ER+ cancer compared to those aged < 50 (57% vs 29%, P = 0.005). 20149218 2010
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE To identify genetic modifiers of this risk, we performed a genome-wide association study in 1,193 individuals with BRCA1 mutations who were diagnosed with invasive breast cancer under age 40 and 1,190 BRCA1 carriers without breast cancer diagnosis over age 35. 20852631 2010
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. 16958968 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE The clinical outcome of contralateral prophylactic mastectomy (CPM) in women with a BRCA1 or BRCA2 mutation and a personal history of invasive breast cancer is unknown. 16052221 2005
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Subjects were population-based samples of Caucasian women that comprised 1,156 incident cases of invasive breast cancer diagnosed before age 40 (including 47 BRCA1 and 36 BRCA2 mutation carriers) and 815 controls from the San Francisco Bay area, California, Ontario, Canada, and Melbourne and Sydney, Australia. 15734957 2005
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Ductal carcinoma in situ is a part of the breast/ovarian cancer syndromes defined by BRCA1 and BRCA2, with mutation rates similar to those found for invasive breast cancer. 15728167 2005
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. 14680495 2004
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE A historical cohort of Ashkenazi Jewish women 65 years or younger with invasive breast carcinoma was tested for BRCA1 founder mutations. p53 overexpression was assessed by immunohistochemistry. 12548593 2003
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE We set out to estimate the frequency of seven previously described founder mutations in BRCA1 and BRCA2 in all eligible French Canadian women diagnosed with invasive breast cancer at one Montreal hospital over a 20-month period. 11453973 2001
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Here we tested the efficacy of these two morphological parameters as BRCA1 mutation indicators and investigated their economic impact, in a population-based survey on a series of women who developed invasive breast cancer by the age of 35 years, regardless of their family history. 10728676 2000
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Approximately 2.0%-2.5% of Ashkenazi Jewish women carry one of three founding mutations in the BRCA1 and BRCA2 genes, and each mutation is associated with a high lifetime risk of invasive breast cancer. 10413426 1999